Elbridge Collin Gerry
Known title: SVP CFO and TreasurerCIK: 0002032118
Associated companies
Transaction History
| CVEO | ▲ Buy | Option Exercise | 2,691 | $0 | 3/3/2026 | View on chart |
| CVEO | ▼ Sell | Other | 2,691 | $73K | 3/3/2026 | View on chart |
| CVEO | ▲ Buy | Option Exercise | 5,699 | $0 | 3/2/2026 | View on chart |
| CVEO | ▼ Sell | Other | 5,699 | $159K | 3/2/2026 | View on chart |
| CVEO | ▲ Buy | Option Exercise | 3,701 | $0 | 2/23/2026 | View on chart |
| CVEO | ▼ Sell | Other | 3,701 | $102K | 2/23/2026 | View on chart |
| CVEO | ▲ Buy | Grant | 1,740 | $0 | 2/23/2026 | View on chart |
| CVEO | ▼ Sell | Tax Withholding | 605 | $17K | 2/23/2026 | View on chart |
| CVEO | ▲ Buy | Option Exercise | 5,678 | — | 3/2/2025 | View on chart |
| CVEO | ▼ Sell | Other | 5,678 | $122K | 3/2/2025 | View on chart |
| CVEO | ▲ Buy | Option Exercise | 4,981 | $0 | 2/25/2025 | View on chart |
| CVEO | ▼ Sell | Other | 4,981 | $134K | 2/25/2025 | View on chart |
| CVEO | ▲ Buy | Grant | 3,247 | $0 | 2/25/2025 | View on chart |
| CVEO | ▼ Sell | Tax Withholding | 1,316 | $35K | 2/25/2025 | View on chart |
| CVEO | ▲ Buy | Option Exercise | 3,701 | — | 2/23/2025 | View on chart |
| CVEO | ▼ Sell | Other | 3,701 | $101K | 2/23/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Civeo (CVEO) receives new analyst coverage and price targets
Roth Capital began coverage of Civeo and issued a $39 price target. Northland Capital also started coverage, assigning an Outperform rating and a $42 target. Both firms' reports add fresh analyst attention to the stock. The targets sit above the recent 52‑week high of $36.50, suggesting expectations of further upside.
Civeo (CVEO) receives new analyst coverage and price targets. Roth Capital began coverage of Civeo and issued a $39 price target. Northland Capital also started coverage, assigning an Outperform rating and a $42 target. Both firms' reports add fresh analyst attention to the stock. The targets sit above the recent 52‑week high of $36.50, suggesting expectations of further upside.